Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that new preclinical data for EDP-235, its lead oral protease inhibitor specifically designed for the treatment of COVID-19, will be presented at the International Society for Influenza and Other Respiratory Virus Diseases (ISIRV)-World Health Organization Virtual Conference (WHO): COVID-19, Influenza and RSV: Surveillance-Informed Prevention and Treatment. The conference is being held virtually on October 19 – October 21, 2021.
Poster Presentation:
Date: October 19, 2021
Time: 8:00 a.m. CET
Poster #120: "EDP-235, A Potential Oral, Once-Daily Antiviral Treatment and Preventative for COVID-19"
Presenter: Li-Juan Jiang, Ph.D.
Posters will be available to view on the conference platform during the conference and for three months thereafter. Further information about the ISIRV-WHO Virtual Conference 2021 can be found here.
https://finance.yahoo.com/news/preclinical-data-edp-235-enanta-121600817.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.